Daiichi Floxin otic will be launched in mid-February; product inaugurates Daiichi self-marketing in U.S..
Executive Summary
DAIICHI FLOXIN OTIC WILL BE IN LAUNCHED MID-FEBRUARY, the company said following FDA approval of the ofloxacin otic solution Dec. 16. The product will be available in pharmacies by the end of January. Daiichi will promote the product with a 54-person sales force, double the size of the Japanese firm's existing team of U.S. sales representatives. Floxin otic will be co-promoted by Johnson & Johnson's Ortho McNeil and McNeil Consumer Products sales forces. Ortho McNeil markets oral and I.V. Floxin in the U.S.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth